Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalICUI +0.17%81 3-Year EBITDA Growth Rate is 14.30% as of Jun. 2026, which is 21% above its 10-year median of 11.80. GuruFocus rates ICUI with a GF Score™ of 81/100 and a GF Value™ of $120.63 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 690 Medical Devices & Instruments companies, ICU Medical ranks better than 57.54% on this metric.
During the past 12 months, ICU Medical's average EBITDA Per Share Growth Rate was -13.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 8.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of ICU Medical was 35.00% per year. The lowest was -19.80% per year. And the median was 11.80% per year.
ICU Medical (NAS:ICUI) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ICU Medical 3-Year EBITDA Growth Rate Related Terms
ICUI vs NVST, MMSI, MMED: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ICU Medical's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.30% mean?
ICU Medical (ICUI) has a 3-Year EBITDA Growth Rate of 14.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ICU Medical and its competitors. This is 21% above median its historical median of 11.80. According to the industry distribution chart, ICU Medical ranks #293 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 42.5%.
Is ICU Medical's 3-Year EBITDA Growth Rate too high?
ICU Medical's current 3-Year EBITDA Growth Rate of 14.30% is 21% above median its 10-year median of 11.80. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. ICU Medical's value of 14.30% is 74.4% above this industry median. Based on the distribution chart, ICU Medical ranks #293 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ICU Medical has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's 3-Year EBITDA Growth Rate compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #293 out of 690 companies for 3-Year EBITDA Growth Rate. This puts ICU Medical in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. ICU Medical's value of 14.30% is 74.4% above this benchmark. While the company's 10-year median is 11.80 vs. the industry median of 8.20, ICU Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current 3-Year EBITDA Growth Rate of 14.30% is 74.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ICU Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current 3-Year EBITDA Growth Rate is 14.30%, which is 21% above median its own 10-year median of 11.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (ICUI) is currently considered Significantly Overvalued. The stock's GF Value™ is $120.63, compared to a current price of $183.00 — trading 51.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.30%, which is 21% above median its 10-year median of 11.80 and 74.4% above the Medical Devices & Instruments industry median of 8.20. ICU Medical's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ICU Medical (ICUI), the current 3-Year EBITDA Growth Rate is 14.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (ICUI) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of $183.00 is trading 51.7% above its estimated GF Value™ of $120.63.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for ICUI:
3-Year EBITDA Growth Rate: 14.30% (21% above median its 10-year median of 11.80)
GF Value™: $120.63 vs. price of $183.00 (51.7% above fair value)
Industry Position: 74.4% above the Medical Devices & Instruments median (#293 of 690)
No single metric tells the full story. See the ICUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
81GF Score
Get the complete analysis for ICUI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICUI has been successfully added to your 
